All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Two large-scale studies provide new data on genes, inherited variations, and de novo mutations associated with autism spectrum disorder. Some of them are also associated with other neurological conditions, like developmental delay, or schizophrenia.
Learning and memory are complex processes that involve many genes, cell types and brain circuits. Genetic screening performed by researchers have identified potassium voltage-gated channel subfamily C member 3 (KCNC3) to be involved in the hippocampal learning and memory processes in mice.
Two large-scale studies provide new data on genes, inherited variations, and de novo mutations associated with autism spectrum disorder (ASD). Some of them are also associated with other neurological conditions, like developmental delay (DD), or schizophrenia.
Neuron-targeting of caveolin-1 (Cav-1) using AAV9 delivery and a synapsin-driven Cav-1 engineered construct, SynCav1, showed therapeutic potential in the hSOD1G93A model of familial amyotrophic lateral sclerosis (ALS).
A fusion protein removed beta-amyloid plaque without producing the neurotoxic inflammation associated with other treatments, such as aducanumab immunotherapy. It is based on the alphaA Beta-Gas6 fusion protein developed in a mouse model of Alzheimer's disease by a team of researchers at The Korea Advanced Institute of Science and Technology in South Korea.
A fusion protein removed beta-amyloid plaque without producing the neurotoxic inflammation associated with other treatments, such as aducanumab immunotherapy. It is based on the alphaA Beta-Gas6 fusion protein developed in a mouse model of Alzheimer's disease (AD) by a team of researchers at The Korea Advanced Institute of Science and Technology (KAIST) in South Korea.
Biofront Therapeutics has identified fMet-Leu-Phe receptor (fMLP; FPR1) antagonists reported to be useful for the treatment of glioblastoma, traumatic brain injury and stroke.
HiberCell has described eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and spinocerebellar ataxia.
Saniona has announced its program to develop small molecules targeting Kv7 ion channels to treat epilepsy has made sufficient progress to move into lead optimization.
RSS
